Related Experiment Video
Updated: Apr 26, 2026

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer
Xiaoping Li1, Weiliang Zhu, Zhenzhu Chen
1Departments of aPathology bOncology, Zhujiang Hospital, NanFang Medical University cDepartment of Organ Transplantation, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Abstract:
Fibroblast growth factor-inducible 14 (Fn14) has been reported to play an oncogene role in many types of cancer. However, its biological functions in small-cell lung cancer (SCLC) remain unknown. The aim of this study is to investigate the roles of Fn14 in the cell growth and chemoresistance of SCLC and its possible molecular mechanism. Expression of Fn14 was examined in 51 cases of SCLC tissues by immunohistochemistry. Overexpression or knockdown of Fn14 was carried out in SCLC multidrug-resistant cell lines (H69AR and H446AR) and the parental cell lines (H69 and H446) to assess its influence on cell growth and chemoresistance. The results showed that Fn14 was expressed in 50.98% (26/51) of SCLC. Overexpression of Fn14 was associated with the poor pathologic stage of SCLC (P < 0.05 by the Fisher's exact test) and the shorter survival time (by the Kaplan-Meier method). Enforced expression of Fn14 in H69 and H446 cells promoted cell growth and enhanced multidrug resistance by decreasing cell apoptosis and increasing G2-phase cell accumulation. Inhibition of Fn14 expression using Fn14 shRNA in H69AR and H446AR cells inhibited cell growth and sensitized cancer cells to chemotherapeutic drugs by increasing drug-induced cell apoptosis accompanied by G1, S phase arrest. Furthermore, elevated expression of Fn14 in H69 and H446 cells can lead to increased expression of Bcl-xl and activity of nuclear factor-κB (NF-κB). Similar results were observed by Fn14 knockdown H69AR and H446AR cells. Bcl-xl expression regulated by Fn14 was dependent on NF-κB activation. Our results suggest that Fn14 modulates cell growth and drug resistance by upregulating Bcl-xl expression through the NF-κB pathway. All findings provide insight into the Fn14 signaling mechanism and Fn14 may be a potentially novel target for interfering with cancer growth and chemoresistance in SCLC.
Insights
Fibroblast growth factor-inducible 14 (Fn14) promotes small-cell lung cancer (SCLC) growth and chemoresistance by upregulating Bcl-xl via the NF-κB pathway. Targeting Fn14 may offer new therapeutic strategies for SCLC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Fibroblast growth factor-inducible 14 (Fn14) is implicated as an oncogene in various cancers.
- The role of Fn14 in small-cell lung cancer (SCLC) remains largely unexplored.
- Understanding Fn14's function in SCLC is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the biological functions of Fn14 in SCLC cell growth and chemoresistance.
- To elucidate the molecular mechanisms underlying Fn14's effects in SCLC.
- To assess Fn14 as a potential therapeutic target for SCLC.
Main Methods:
- Immunohistochemistry was used to examine Fn14 expression in 51 SCLC tissue samples.
- Fn14 was overexpressed or knocked down in SCLC cell lines (H69, H446, H69AR, H446AR) to study its impact on cell growth and chemoresistance.
- Cell apoptosis, cell cycle progression, Bcl-xl expression, and nuclear factor-κB (NF-κB) activity were analyzed.
Main Results:
- Fn14 was expressed in 50.98% of SCLC cases and associated with advanced pathologic stage and shorter survival.
- Overexpression of Fn14 promoted SCLC cell growth, enhanced multidrug resistance, decreased apoptosis, and increased G2-phase accumulation.
- Inhibition of Fn14 reduced cell growth, sensitized cells to chemotherapy, increased apoptosis, and induced G1/S phase arrest, mediated by the NF-κB/Bcl-xl pathway.
Conclusions:
- Fn14 plays a significant role in promoting SCLC cell proliferation and chemoresistance.
- The Fn14 signaling pathway, involving NF-κB and Bcl-xl, is a key mechanism in SCLC progression.
- Fn14 represents a promising novel therapeutic target for SCLC treatment.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply
Negative Regulator Molecules
Cells Coordinate Growth and Proliferation

